Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/4/2013 |
| Start Date: | September 2011 |
| End Date: | February 2013 |
| Contact: | Novartis Pharmaceuticals |
| Phone: | +1(862)778-8300 |
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate
to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's
disease.
Inclusion Criteria:
- Patients with Parkinson's disease
- Patients with dyskinesias for at least 3 months
- Patients with moderate to severe dyskinesias
- Patients on L-dopa treatment for at least 3 years
Exclusion Criteria:
- Patients with atypical Parkinson's disease
- Patients who have had prior surgery for Parkinson's disease
- Patients who are cognitively impaired, have psychosis, have confusional states or
hallucinate
- Patients who received neuroleptics or anti-psychotics within 2 months
- Women of child-bearing potential
Other protocol-defined inclusion/exclusion criteria may apply.
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials